Dennis Roop
Concepts (837)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermis | 84 | 2024 | 157 | 8.710 |
Why?
| | Keratins | 113 | 2016 | 171 | 6.800 |
Why?
| | Keratinocytes | 56 | 2024 | 251 | 4.260 |
Why?
| | Skin Neoplasms | 57 | 2024 | 853 | 3.940 |
Why?
| | Membrane Proteins | 39 | 2022 | 1156 | 3.660 |
Why?
| | Skin | 53 | 2024 | 764 | 3.250 |
Why?
| | Trans-Activators | 26 | 2013 | 394 | 2.860 |
Why?
| | Papilloma | 31 | 2011 | 52 | 2.080 |
Why?
| | Phosphoproteins | 17 | 2013 | 335 | 2.080 |
Why?
| | Cell Transformation, Neoplastic | 25 | 2016 | 332 | 2.070 |
Why?
| | Cell Differentiation | 74 | 2024 | 1999 | 2.030 |
Why?
| | Hyperkeratosis, Epidermolytic | 17 | 2008 | 21 | 1.990 |
Why?
| | Mice, Transgenic | 66 | 2017 | 2176 | 1.920 |
Why?
| | NF-E2-Related Factor 2 | 7 | 2022 | 94 | 1.890 |
Why?
| | Stem Cells | 19 | 2017 | 603 | 1.860 |
Why?
| | Mice | 189 | 2024 | 18057 | 1.750 |
Why?
| | Genes, ras | 25 | 2012 | 94 | 1.530 |
Why?
| | Animals | 232 | 2024 | 37579 | 1.470 |
Why?
| | Hair Follicle | 14 | 2020 | 48 | 1.390 |
Why?
| | Genetic Therapy | 12 | 2014 | 315 | 1.240 |
Why?
| | Vitiligo | 8 | 2024 | 42 | 1.240 |
Why?
| | Mutation | 37 | 2024 | 3999 | 1.120 |
Why?
| | Melanocytes | 8 | 2024 | 66 | 1.110 |
Why?
| | Point Mutation | 13 | 2009 | 237 | 1.100 |
Why?
| | Skin Diseases | 8 | 2014 | 148 | 1.040 |
Why?
| | Carcinoma, Squamous Cell | 20 | 2016 | 640 | 1.020 |
Why?
| | Induced Pluripotent Stem Cells | 6 | 2024 | 265 | 1.020 |
Why?
| | Transforming Growth Factor alpha | 10 | 2000 | 57 | 0.930 |
Why?
| | Collagen Type VII | 2 | 2024 | 28 | 0.920 |
Why?
| | Cell Division | 20 | 2016 | 792 | 0.910 |
Why?
| | Ichthyosis | 7 | 2016 | 13 | 0.910 |
Why?
| | Mice, Knockout | 35 | 2018 | 3064 | 0.900 |
Why?
| | Epidermolysis Bullosa Dystrophica | 2 | 2024 | 42 | 0.900 |
Why?
| | Disease Models, Animal | 31 | 2020 | 4407 | 0.900 |
Why?
| | Gene Expression Regulation | 31 | 2016 | 2604 | 0.850 |
Why?
| | Phenotype | 28 | 2021 | 3172 | 0.850 |
Why?
| | Ectodermal Dysplasia | 5 | 2009 | 19 | 0.850 |
Why?
| | Cornified Envelope Proline-Rich Proteins | 7 | 2018 | 9 | 0.830 |
Why?
| | Morphogenesis | 7 | 2010 | 171 | 0.830 |
Why?
| | Base Sequence | 49 | 2016 | 2169 | 0.820 |
Why?
| | Gene Expression Regulation, Developmental | 14 | 2015 | 873 | 0.810 |
Why?
| | Melanoma | 10 | 2020 | 792 | 0.810 |
Why?
| | DNA-Binding Proteins | 15 | 2015 | 1478 | 0.800 |
Why?
| | Ultraviolet Rays | 9 | 2024 | 401 | 0.800 |
Why?
| | Genes, fos | 10 | 2000 | 37 | 0.790 |
Why?
| | Neoplasms, Experimental | 4 | 2019 | 174 | 0.780 |
Why?
| | Genes, p53 | 10 | 2012 | 68 | 0.770 |
Why?
| | Transgenes | 13 | 2016 | 185 | 0.760 |
Why?
| | Tetradecanoylphorbol Acetate | 21 | 2010 | 156 | 0.760 |
Why?
| | Tumor Suppressor Proteins | 8 | 2009 | 325 | 0.740 |
Why?
| | Proto-Oncogene Proteins c-myc | 6 | 2010 | 163 | 0.730 |
Why?
| | Tumor Suppressor Protein p53 | 6 | 2011 | 526 | 0.720 |
Why?
| | Skin Pigmentation | 4 | 2024 | 48 | 0.710 |
Why?
| | Cells, Cultured | 39 | 2024 | 4199 | 0.710 |
Why?
| | Intermediate Filament Proteins | 22 | 2012 | 58 | 0.710 |
Why?
| | Jews | 1 | 2021 | 24 | 0.710 |
Why?
| | Gene Expression Regulation, Neoplastic | 18 | 2015 | 1430 | 0.700 |
Why?
| | Skin Physiological Phenomena | 7 | 2008 | 25 | 0.700 |
Why?
| | Neoplastic Stem Cells | 7 | 2016 | 407 | 0.640 |
Why?
| | Cell Lineage | 5 | 2010 | 351 | 0.640 |
Why?
| | Ichthyosis, Lamellar | 2 | 2016 | 9 | 0.620 |
Why?
| | Cytoskeletal Proteins | 9 | 2012 | 156 | 0.620 |
Why?
| | Intravital Microscopy | 1 | 2019 | 24 | 0.620 |
Why?
| | Transcription Factors | 16 | 2015 | 1703 | 0.610 |
Why?
| | Molecular Sequence Data | 34 | 2012 | 2917 | 0.600 |
Why?
| | Genes, myc | 4 | 2011 | 48 | 0.600 |
Why?
| | Signal Transduction | 22 | 2020 | 5148 | 0.560 |
Why?
| | Pluripotent Stem Cells | 2 | 2010 | 80 | 0.560 |
Why?
| | Hair | 6 | 2012 | 89 | 0.550 |
Why?
| | Hedgehog Proteins | 7 | 2017 | 200 | 0.550 |
Why?
| | Genes | 15 | 2008 | 229 | 0.540 |
Why?
| | Immunity, Cellular | 1 | 2019 | 267 | 0.540 |
Why?
| | Skin Diseases, Genetic | 6 | 2020 | 13 | 0.540 |
Why?
| | Keratin-6 | 5 | 2016 | 6 | 0.520 |
Why?
| | Mice, Mutant Strains | 14 | 2016 | 306 | 0.520 |
Why?
| | Promoter Regions, Genetic | 17 | 2016 | 1241 | 0.500 |
Why?
| | Multipotent Stem Cells | 3 | 2010 | 20 | 0.490 |
Why?
| | Protein Isoforms | 8 | 2008 | 398 | 0.480 |
Why?
| | Amino Acid Sequence | 30 | 2012 | 2152 | 0.480 |
Why?
| | Head and Neck Neoplasms | 5 | 2016 | 553 | 0.480 |
Why?
| | Humans | 132 | 2024 | 140898 | 0.480 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2016 | 120 | 0.480 |
Why?
| | Ultraviolet Therapy | 4 | 2024 | 17 | 0.470 |
Why?
| | Keratoderma, Palmoplantar | 3 | 2014 | 6 | 0.470 |
Why?
| | Cell Proliferation | 14 | 2024 | 2497 | 0.460 |
Why?
| | Pachyonychia Congenita | 3 | 2014 | 4 | 0.450 |
Why?
| | Transforming Growth Factor beta | 8 | 2009 | 498 | 0.450 |
Why?
| | Viral Proteins | 4 | 2002 | 369 | 0.440 |
Why?
| | Genetic Vectors | 7 | 2013 | 336 | 0.440 |
Why?
| | Tretinoin | 11 | 2014 | 122 | 0.440 |
Why?
| | Gene Deletion | 8 | 2012 | 388 | 0.430 |
Why?
| | Keratosis | 7 | 2000 | 16 | 0.430 |
Why?
| | Epithelium | 14 | 2004 | 315 | 0.430 |
Why?
| | Animals, Newborn | 23 | 2007 | 866 | 0.430 |
Why?
| | Cell Culture Techniques | 3 | 2014 | 368 | 0.420 |
Why?
| | DNA | 24 | 2018 | 1438 | 0.420 |
Why?
| | Cadherins | 3 | 2016 | 201 | 0.420 |
Why?
| | Cell Cycle | 3 | 2012 | 598 | 0.420 |
Why?
| | Mice, Inbred ICR | 10 | 2011 | 118 | 0.410 |
Why?
| | Genes, Dominant | 6 | 2016 | 97 | 0.410 |
Why?
| | Amniotic Fluid | 2 | 2012 | 79 | 0.410 |
Why?
| | Mosaicism | 5 | 2014 | 74 | 0.400 |
Why?
| | Nails, Malformed | 2 | 2005 | 7 | 0.390 |
Why?
| | Up-Regulation | 8 | 2020 | 856 | 0.390 |
Why?
| | Abnormalities, Multiple | 3 | 2014 | 197 | 0.380 |
Why?
| | Proteomics | 2 | 2016 | 1136 | 0.380 |
Why?
| | Keratin-10 | 8 | 2016 | 8 | 0.380 |
Why?
| | Eyelids | 2 | 2009 | 42 | 0.380 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 17 | 2010 | 24 | 0.380 |
Why?
| | Wnt Signaling Pathway | 2 | 2024 | 202 | 0.380 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2012 | 36 | 0.370 |
Why?
| | Melanoma, Experimental | 3 | 1998 | 111 | 0.370 |
Why?
| | DNA Primers | 13 | 2010 | 508 | 0.370 |
Why?
| | Transcription, Genetic | 23 | 2017 | 1485 | 0.370 |
Why?
| | Cleft Lip | 2 | 2009 | 59 | 0.370 |
Why?
| | Carcinogens | 12 | 2010 | 125 | 0.360 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2012 | 438 | 0.360 |
Why?
| | Cleft Palate | 2 | 2009 | 75 | 0.360 |
Why?
| | Oncogene Proteins v-fos | 6 | 1999 | 11 | 0.360 |
Why?
| | Mutation, Missense | 3 | 2016 | 340 | 0.360 |
Why?
| | Gene Transfer Techniques | 4 | 2002 | 176 | 0.360 |
Why?
| | Wound Healing | 6 | 2010 | 350 | 0.350 |
Why?
| | Apoptosis | 9 | 2012 | 2571 | 0.350 |
Why?
| | Calcium | 12 | 2010 | 1190 | 0.340 |
Why?
| | Hyperplasia | 12 | 2002 | 174 | 0.340 |
Why?
| | Centrosome | 4 | 2012 | 71 | 0.340 |
Why?
| | Proteins | 3 | 2016 | 1013 | 0.340 |
Why?
| | Pedigree | 11 | 2000 | 511 | 0.330 |
Why?
| | RNA, Messenger | 35 | 2016 | 2822 | 0.330 |
Why?
| | Integrases | 5 | 2004 | 123 | 0.320 |
Why?
| | Alleles | 7 | 2016 | 883 | 0.320 |
Why?
| | Gene Targeting | 5 | 2008 | 83 | 0.310 |
Why?
| | Stem Cell Niche | 1 | 2010 | 58 | 0.310 |
Why?
| | Epidermolysis Bullosa Simplex | 4 | 2004 | 10 | 0.310 |
Why?
| | Transcription Factor AP-2 | 2 | 2008 | 82 | 0.300 |
Why?
| | Immunotherapy | 3 | 2020 | 643 | 0.300 |
Why?
| | Genes, Recessive | 2 | 2021 | 78 | 0.300 |
Why?
| | Mice, Nude | 12 | 2016 | 689 | 0.300 |
Why?
| | Female | 74 | 2024 | 75540 | 0.290 |
Why?
| | Polymerase Chain Reaction | 13 | 2002 | 1052 | 0.280 |
Why?
| | Mice, Inbred Strains | 13 | 2010 | 412 | 0.280 |
Why?
| | Keratins, Type II | 1 | 2007 | 2 | 0.270 |
Why?
| | Adenoviridae | 3 | 1998 | 200 | 0.270 |
Why?
| | Fluorescent Antibody Technique | 19 | 2004 | 386 | 0.270 |
Why?
| | Aurora Kinases | 3 | 2012 | 28 | 0.260 |
Why?
| | Octamer Transcription Factor-3 | 1 | 2007 | 18 | 0.260 |
Why?
| | Lipid Metabolism | 5 | 2018 | 525 | 0.260 |
Why?
| | Aurora Kinase A | 3 | 2012 | 55 | 0.260 |
Why?
| | Disease Progression | 6 | 2019 | 2791 | 0.260 |
Why?
| | Keratin-14 | 6 | 2012 | 15 | 0.260 |
Why?
| | Transcription Factor AP-1 | 3 | 2014 | 88 | 0.260 |
Why?
| | Mice, Inbred BALB C | 17 | 2020 | 1271 | 0.250 |
Why?
| | Mifepristone | 9 | 2009 | 63 | 0.250 |
Why?
| | Skin Transplantation | 6 | 2024 | 85 | 0.250 |
Why?
| | Amino Acid Substitution | 4 | 2000 | 309 | 0.250 |
Why?
| | Proto-Oncogenes | 1 | 2006 | 28 | 0.250 |
Why?
| | Ichthyosiform Erythroderma, Congenital | 2 | 2018 | 6 | 0.250 |
Why?
| | Genes, Reporter | 4 | 2009 | 272 | 0.240 |
Why?
| | Models, Biological | 8 | 2016 | 1822 | 0.240 |
Why?
| | Homeostasis | 3 | 2020 | 636 | 0.240 |
Why?
| | Kelch-Like ECH-Associated Protein 1 | 3 | 2016 | 11 | 0.240 |
Why?
| | Cell Line | 14 | 2018 | 2879 | 0.240 |
Why?
| | Genomic Instability | 4 | 2011 | 57 | 0.230 |
Why?
| | Male | 50 | 2024 | 69893 | 0.230 |
Why?
| | Oncogene Protein p21(ras) | 4 | 2004 | 15 | 0.230 |
Why?
| | Gene Expression | 12 | 2015 | 1490 | 0.230 |
Why?
| | Mice, Inbred C57BL | 19 | 2015 | 5895 | 0.230 |
Why?
| | Intermediate Filaments | 6 | 2015 | 26 | 0.230 |
Why?
| | Mouth Neoplasms | 2 | 2004 | 89 | 0.230 |
Why?
| | Keratin-1 | 2 | 2016 | 2 | 0.220 |
Why?
| | Skin Diseases, Vesiculobullous | 2 | 1999 | 18 | 0.220 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2024 | 5 | 0.220 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2015 | 248 | 0.220 |
Why?
| | Lipids | 4 | 2018 | 689 | 0.220 |
Why?
| | Prenatal Diagnosis | 2 | 1998 | 190 | 0.220 |
Why?
| | ras Proteins | 4 | 2013 | 145 | 0.220 |
Why?
| | Protein Precursors | 9 | 2006 | 134 | 0.220 |
Why?
| | Retinoids | 2 | 1997 | 34 | 0.210 |
Why?
| | beta Catenin | 3 | 2020 | 258 | 0.210 |
Why?
| | Heterozygote | 4 | 2010 | 308 | 0.210 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2024 | 85 | 0.210 |
Why?
| | Sequence Analysis, DNA | 6 | 2016 | 817 | 0.200 |
Why?
| | Cocarcinogenesis | 4 | 2000 | 13 | 0.200 |
Why?
| | Lac Operon | 2 | 2000 | 44 | 0.200 |
Why?
| | Proto-Oncogene Proteins | 5 | 2013 | 624 | 0.200 |
Why?
| | Transfection | 10 | 2017 | 936 | 0.200 |
Why?
| | Transduction, Genetic | 4 | 2009 | 135 | 0.200 |
Why?
| | Tongue | 2 | 2001 | 81 | 0.190 |
Why?
| | Antioxidants | 2 | 2020 | 596 | 0.190 |
Why?
| | Oncogenes | 5 | 1994 | 118 | 0.190 |
Why?
| | Cilia | 2 | 2017 | 172 | 0.190 |
Why?
| | Wnt Proteins | 3 | 2010 | 136 | 0.190 |
Why?
| | Cytoskeleton | 8 | 1994 | 194 | 0.190 |
Why?
| | Epithelial Cells | 14 | 2006 | 1113 | 0.190 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 985 | 0.190 |
Why?
| | Alopecia | 4 | 2005 | 32 | 0.190 |
Why?
| | Cell Membrane | 7 | 2015 | 720 | 0.190 |
Why?
| | Hindlimb | 2 | 1999 | 134 | 0.190 |
Why?
| | Micromanipulation | 1 | 2002 | 14 | 0.180 |
Why?
| | Human Growth Hormone | 1 | 2002 | 46 | 0.180 |
Why?
| | Chromosome Mapping | 5 | 2016 | 504 | 0.180 |
Why?
| | Chile | 1 | 2021 | 24 | 0.180 |
Why?
| | Colombia | 1 | 2021 | 41 | 0.180 |
Why?
| | Hair Diseases | 1 | 2001 | 10 | 0.180 |
Why?
| | Nail Diseases | 1 | 2001 | 9 | 0.180 |
Why?
| | Permeability | 3 | 2016 | 165 | 0.180 |
Why?
| | Microscopy, Electron | 10 | 2002 | 440 | 0.180 |
Why?
| | Blister | 1 | 2001 | 40 | 0.180 |
Why?
| | I-kappa B Kinase | 4 | 2009 | 54 | 0.170 |
Why?
| | Molecular Imprinting | 1 | 2020 | 5 | 0.170 |
Why?
| | Mexico | 1 | 2021 | 229 | 0.170 |
Why?
| | Neoplasm Transplantation | 6 | 2016 | 250 | 0.170 |
Why?
| | Microscopy, Confocal | 1 | 2002 | 323 | 0.170 |
Why?
| | Carcinoma | 5 | 1995 | 230 | 0.170 |
Why?
| | RNA | 6 | 2018 | 929 | 0.160 |
Why?
| | Ceramides | 3 | 2016 | 117 | 0.160 |
Why?
| | Cloning, Molecular | 9 | 2002 | 532 | 0.160 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2008 | 270 | 0.160 |
Why?
| | Regenerative Medicine | 2 | 2019 | 52 | 0.160 |
Why?
| | Adult Stem Cells | 1 | 2020 | 40 | 0.160 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 32 | 0.160 |
Why?
| | Blotting, Western | 8 | 2007 | 1231 | 0.160 |
Why?
| | Cell Membrane Permeability | 1 | 2020 | 82 | 0.160 |
Why?
| | Fibroblasts | 6 | 2024 | 1017 | 0.160 |
Why?
| | Molecular Weight | 15 | 1990 | 327 | 0.160 |
Why?
| | Papillomaviridae | 3 | 2016 | 121 | 0.160 |
Why?
| | Zebrafish Proteins | 1 | 2002 | 292 | 0.160 |
Why?
| | Bimatoprost | 1 | 2019 | 3 | 0.160 |
Why?
| | Genetic Linkage | 4 | 1999 | 288 | 0.160 |
Why?
| | Precancerous Conditions | 4 | 2004 | 161 | 0.160 |
Why?
| | Immunologic Surveillance | 1 | 2019 | 26 | 0.150 |
Why?
| | Antineoplastic Agents | 5 | 2016 | 2156 | 0.150 |
Why?
| | Guided Tissue Regeneration | 1 | 2019 | 13 | 0.150 |
Why?
| | Crosses, Genetic | 4 | 2010 | 133 | 0.150 |
Why?
| | Arginine | 2 | 2007 | 257 | 0.150 |
Why?
| | Skin Aging | 2 | 1997 | 20 | 0.150 |
Why?
| | Alopecia Areata | 1 | 2019 | 13 | 0.150 |
Why?
| | Deafness | 1 | 2000 | 78 | 0.150 |
Why?
| | Threonine | 1 | 1999 | 47 | 0.150 |
Why?
| | Asparagine | 1 | 1999 | 32 | 0.150 |
Why?
| | Thymidine Kinase | 2 | 1998 | 15 | 0.150 |
Why?
| | Zinc Finger Protein GLI1 | 2 | 2017 | 26 | 0.150 |
Why?
| | Janus Kinase Inhibitors | 1 | 2019 | 27 | 0.150 |
Why?
| | Caspase 14 | 1 | 2018 | 1 | 0.150 |
Why?
| | Ovalbumin | 7 | 1981 | 196 | 0.140 |
Why?
| | Tumor Cells, Cultured | 7 | 2016 | 956 | 0.140 |
Why?
| | Simplexvirus | 2 | 1998 | 82 | 0.140 |
Why?
| | Microscopy, Immunoelectron | 4 | 2016 | 45 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-jun | 2 | 1999 | 56 | 0.140 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 903 | 0.140 |
Why?
| | Cytoprotection | 1 | 2018 | 57 | 0.140 |
Why?
| | Cellular Reprogramming Techniques | 1 | 2018 | 11 | 0.140 |
Why?
| | Autoimmunity | 1 | 2024 | 906 | 0.140 |
Why?
| | Transplantation, Heterologous | 3 | 2011 | 193 | 0.140 |
Why?
| | Caspase 3 | 2 | 2010 | 248 | 0.140 |
Why?
| | Potoroidae | 2 | 2007 | 3 | 0.140 |
Why?
| | Oncogene Proteins, Viral | 2 | 1994 | 22 | 0.130 |
Why?
| | Gene Silencing | 2 | 2016 | 197 | 0.130 |
Why?
| | Mammary Glands, Animal | 2 | 2006 | 131 | 0.130 |
Why?
| | Desmosomes | 2 | 2016 | 21 | 0.130 |
Why?
| | Receptors, Retinoic Acid | 1 | 1997 | 41 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 3 | 2013 | 236 | 0.130 |
Why?
| | Protein Multimerization | 1 | 2018 | 194 | 0.130 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 1997 | 57 | 0.130 |
Why?
| | Syndrome | 3 | 2009 | 377 | 0.130 |
Why?
| | Neovascularization, Pathologic | 1 | 1998 | 295 | 0.130 |
Why?
| | Mutagenesis, Site-Directed | 4 | 1999 | 377 | 0.130 |
Why?
| | Dermatitis, Atopic | 1 | 2020 | 331 | 0.130 |
Why?
| | Nucleic Acid Hybridization | 13 | 1991 | 189 | 0.130 |
Why?
| | Glucosylceramides | 1 | 2016 | 6 | 0.130 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2016 | 26 | 0.130 |
Why?
| | Kallikreins | 1 | 2016 | 27 | 0.130 |
Why?
| | Exons | 2 | 2016 | 352 | 0.130 |
Why?
| | Recombinant Fusion Proteins | 2 | 1996 | 672 | 0.120 |
Why?
| | Bone Morphogenetic Protein 4 | 2 | 2014 | 43 | 0.120 |
Why?
| | Gene Amplification | 2 | 2011 | 103 | 0.120 |
Why?
| | Side-Population Cells | 2 | 2013 | 8 | 0.120 |
Why?
| | SOXB1 Transcription Factors | 1 | 2016 | 65 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2016 | 100 | 0.120 |
Why?
| | Microscopy, Fluorescence | 5 | 2007 | 418 | 0.120 |
Why?
| | Cell Movement | 5 | 2019 | 982 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2013 | 210 | 0.120 |
Why?
| | Genes, Regulator | 2 | 1993 | 36 | 0.120 |
Why?
| | Amino Acid Motifs | 1 | 2016 | 225 | 0.120 |
Why?
| | Bromodeoxyuridine | 3 | 2001 | 80 | 0.120 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2016 | 150 | 0.120 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1999 | 403 | 0.120 |
Why?
| | Cetuximab | 1 | 2015 | 105 | 0.120 |
Why?
| | Hematopoietic Stem Cells | 3 | 2015 | 411 | 0.110 |
Why?
| | Receptors, Progesterone | 3 | 2002 | 336 | 0.110 |
Why?
| | Hand Deformities, Congenital | 1 | 2014 | 10 | 0.110 |
Why?
| | Trachea | 4 | 1993 | 255 | 0.110 |
Why?
| | Chloracne | 1 | 2014 | 1 | 0.110 |
Why?
| | Cricetinae | 9 | 1994 | 300 | 0.110 |
Why?
| | Keratin-2 | 3 | 2000 | 3 | 0.110 |
Why?
| | RNA, Neoplasm | 6 | 1995 | 79 | 0.110 |
Why?
| | Dermis | 2 | 2010 | 33 | 0.110 |
Why?
| | Genes, Tumor Suppressor | 2 | 2004 | 84 | 0.110 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2014 | 68 | 0.100 |
Why?
| | Cellular Reprogramming | 1 | 2014 | 98 | 0.100 |
Why?
| | Transcriptional Activation | 4 | 2007 | 377 | 0.100 |
Why?
| | Hormones | 2 | 1994 | 138 | 0.100 |
Why?
| | Embryonic and Fetal Development | 3 | 2002 | 93 | 0.100 |
Why?
| | Recombination, Genetic | 2 | 2008 | 206 | 0.100 |
Why?
| | Smad4 Protein | 1 | 2013 | 35 | 0.100 |
Why?
| | Genetic Engineering | 2 | 2007 | 92 | 0.100 |
Why?
| | Nuclear Proteins | 3 | 2006 | 716 | 0.100 |
Why?
| | DNA Mutational Analysis | 3 | 2018 | 396 | 0.100 |
Why?
| | Vagina | 3 | 1994 | 188 | 0.100 |
Why?
| | Embryoid Bodies | 1 | 2013 | 8 | 0.100 |
Why?
| | Fatty Acid Transport Proteins | 1 | 2012 | 19 | 0.100 |
Why?
| | DNA Restriction Enzymes | 7 | 1998 | 51 | 0.100 |
Why?
| | Keratins, Hair-Specific | 1 | 2012 | 1 | 0.100 |
Why?
| | RNA Splice Sites | 1 | 2012 | 50 | 0.100 |
Why?
| | Polyploidy | 1 | 2012 | 13 | 0.100 |
Why?
| | Models, Animal | 4 | 2013 | 393 | 0.100 |
Why?
| | Polymorphism, Restriction Fragment Length | 3 | 2004 | 68 | 0.100 |
Why?
| | Macromolecular Substances | 7 | 1992 | 224 | 0.090 |
Why?
| | Cell Separation | 2 | 2007 | 317 | 0.090 |
Why?
| | Dermatology | 1 | 2014 | 123 | 0.090 |
Why?
| | Quinone Reductases | 2 | 2002 | 17 | 0.090 |
Why?
| | Carrier Proteins | 2 | 2003 | 746 | 0.090 |
Why?
| | RNA, Small Interfering | 3 | 2012 | 624 | 0.090 |
Why?
| | Binding Sites | 4 | 2006 | 1315 | 0.090 |
Why?
| | Immunohistochemistry | 14 | 2007 | 1726 | 0.090 |
Why?
| | Fetal Diseases | 1 | 1994 | 180 | 0.090 |
Why?
| | Embryo, Mammalian | 3 | 2010 | 234 | 0.090 |
Why?
| | Cancer Vaccines | 3 | 1998 | 166 | 0.090 |
Why?
| | MicroRNAs | 2 | 2015 | 691 | 0.090 |
Why?
| | Cerebellar Ataxia | 1 | 2011 | 13 | 0.090 |
Why?
| | Immunocompetence | 1 | 2011 | 44 | 0.090 |
Why?
| | Regulatory Sequences, Nucleic Acid | 3 | 1999 | 92 | 0.090 |
Why?
| | Cell Count | 2 | 1991 | 325 | 0.090 |
Why?
| | Epitopes | 3 | 1997 | 477 | 0.090 |
Why?
| | Sebaceous Glands | 1 | 2010 | 5 | 0.090 |
Why?
| | Keratolytic Agents | 1 | 2010 | 5 | 0.090 |
Why?
| | Integrins | 1 | 2011 | 95 | 0.090 |
Why?
| | Calcification, Physiologic | 1 | 2011 | 34 | 0.090 |
Why?
| | Introns | 4 | 2004 | 253 | 0.090 |
Why?
| | Carcinogenesis | 3 | 2021 | 215 | 0.090 |
Why?
| | Decidua | 1 | 2010 | 24 | 0.080 |
Why?
| | Ribosomal Proteins | 1 | 2011 | 92 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-fos | 3 | 1999 | 191 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 1993 | 624 | 0.080 |
Why?
| | Nevus | 1 | 2010 | 26 | 0.080 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 699 | 0.080 |
Why?
| | Biomarkers, Tumor | 7 | 2009 | 1243 | 0.080 |
Why?
| | Adenocarcinoma, Sebaceous | 1 | 2010 | 2 | 0.080 |
Why?
| | Sebaceous Gland Neoplasms | 1 | 2010 | 3 | 0.080 |
Why?
| | Genetic Techniques | 2 | 2005 | 67 | 0.080 |
Why?
| | Caspase 7 | 1 | 2010 | 22 | 0.080 |
Why?
| | Aneuploidy | 2 | 2007 | 88 | 0.080 |
Why?
| | In Situ Nick-End Labeling | 2 | 2007 | 126 | 0.080 |
Why?
| | Genotype | 4 | 2015 | 1862 | 0.080 |
Why?
| | Osteoblasts | 1 | 2011 | 136 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2012 | 832 | 0.080 |
Why?
| | Organ Specificity | 4 | 2007 | 311 | 0.080 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2009 | 18 | 0.080 |
Why?
| | Liver Regeneration | 1 | 2010 | 45 | 0.080 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1990 | 68 | 0.080 |
Why?
| | Neoplasms | 2 | 2006 | 2718 | 0.080 |
Why?
| | Teratoma | 1 | 2010 | 121 | 0.080 |
Why?
| | Disease Susceptibility | 5 | 2006 | 352 | 0.080 |
Why?
| | Oviducts | 9 | 1982 | 15 | 0.080 |
Why?
| | Uterus | 1 | 2010 | 220 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2015 | 1067 | 0.080 |
Why?
| | Gene Expression Profiling | 4 | 2015 | 1761 | 0.080 |
Why?
| | Collagen | 2 | 1988 | 460 | 0.080 |
Why?
| | Non-Fibrillar Collagens | 1 | 1988 | 2 | 0.070 |
Why?
| | Selection, Genetic | 1 | 2011 | 263 | 0.070 |
Why?
| | Mitochondria | 1 | 2015 | 974 | 0.070 |
Why?
| | Down-Regulation | 4 | 2009 | 638 | 0.070 |
Why?
| | Osteogenesis | 1 | 2011 | 198 | 0.070 |
Why?
| | Pemphigoid, Bullous | 1 | 1988 | 8 | 0.070 |
Why?
| | Muscle, Smooth | 1 | 1990 | 154 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2012 | 632 | 0.070 |
Why?
| | Receptor, Notch1 | 2 | 2006 | 65 | 0.070 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 331 | 0.070 |
Why?
| | Spindle Apparatus | 1 | 2009 | 104 | 0.070 |
Why?
| | beta-Galactosidase | 2 | 1999 | 78 | 0.070 |
Why?
| | Stress, Physiological | 1 | 2012 | 452 | 0.070 |
Why?
| | Foot | 1 | 2009 | 99 | 0.070 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2005 | 122 | 0.070 |
Why?
| | Hand | 1 | 2009 | 163 | 0.070 |
Why?
| | Genes, Lethal | 2 | 2008 | 30 | 0.070 |
Why?
| | Olfactory Mucosa | 1 | 2008 | 39 | 0.070 |
Why?
| | Integrin beta1 | 2 | 2013 | 25 | 0.070 |
Why?
| | Hoof and Claw | 1 | 2007 | 9 | 0.070 |
Why?
| | Cell Death | 1 | 2009 | 387 | 0.070 |
Why?
| | Bone Marrow | 2 | 2015 | 301 | 0.070 |
Why?
| | Protein Structure, Tertiary | 2 | 2007 | 858 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 466 | 0.070 |
Why?
| | Langerhans Cells | 2 | 1997 | 12 | 0.070 |
Why?
| | Protein Conformation | 6 | 1992 | 939 | 0.070 |
Why?
| | Cytoplasmic Granules | 4 | 2002 | 93 | 0.070 |
Why?
| | Growth Substances | 2 | 1999 | 144 | 0.070 |
Why?
| | Caspase 9 | 1 | 2007 | 57 | 0.070 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 159 | 0.070 |
Why?
| | Adult | 10 | 2020 | 39134 | 0.070 |
Why?
| | Species Specificity | 3 | 2000 | 577 | 0.060 |
Why?
| | Cell Line, Tumor | 5 | 2015 | 3487 | 0.060 |
Why?
| | Chloramphenicol O-Acetyltransferase | 2 | 1999 | 36 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2006 | 433 | 0.060 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2006 | 18 | 0.060 |
Why?
| | Coculture Techniques | 2 | 2024 | 244 | 0.060 |
Why?
| | Cell Adhesion | 3 | 2015 | 468 | 0.060 |
Why?
| | Interleukin-1alpha | 2 | 2020 | 57 | 0.060 |
Why?
| | Microscopy, Fluorescence, Multiphoton | 1 | 2007 | 69 | 0.060 |
Why?
| | Ganciclovir | 2 | 1998 | 53 | 0.060 |
Why?
| | Twist-Related Protein 1 | 1 | 2006 | 9 | 0.060 |
Why?
| | Biological Assay | 1 | 2007 | 131 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1786 | 0.060 |
Why?
| | Mice, SCID | 3 | 2013 | 365 | 0.060 |
Why?
| | Blotting, Northern | 6 | 1992 | 198 | 0.060 |
Why?
| | Glycine | 1 | 2007 | 185 | 0.060 |
Why?
| | Lymphatic Metastasis | 1 | 2007 | 326 | 0.060 |
Why?
| | Phorbols | 1 | 1985 | 10 | 0.060 |
Why?
| | Darier Disease | 1 | 2005 | 2 | 0.060 |
Why?
| | Autoantigens | 1 | 1988 | 425 | 0.060 |
Why?
| | Stomach | 2 | 2006 | 109 | 0.060 |
Why?
| | Models, Genetic | 3 | 2008 | 587 | 0.060 |
Why?
| | Antibodies | 2 | 1985 | 411 | 0.060 |
Why?
| | Nucleic Acid Precursors | 3 | 1980 | 24 | 0.060 |
Why?
| | Protein Structure, Secondary | 2 | 1999 | 368 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2007 | 801 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 1999 | 1361 | 0.060 |
Why?
| | Flow Cytometry | 2 | 2007 | 1195 | 0.060 |
Why?
| | Cyclins | 2 | 1996 | 91 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2012 | 1325 | 0.060 |
Why?
| | Skin Abnormalities | 2 | 2002 | 12 | 0.060 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 180 | 0.060 |
Why?
| | Retinal Dehydrogenase | 2 | 2016 | 29 | 0.060 |
Why?
| | Embryonic Development | 1 | 2005 | 118 | 0.060 |
Why?
| | Cell Cycle Proteins | 2 | 2006 | 632 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 1988 | 605 | 0.060 |
Why?
| | RNA Interference | 3 | 2013 | 468 | 0.060 |
Why?
| | Melanins | 1 | 2024 | 17 | 0.060 |
Why?
| | Cyclopropanes | 1 | 2024 | 75 | 0.050 |
Why?
| | Calcineurin | 1 | 2005 | 107 | 0.050 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 4 | 1990 | 335 | 0.050 |
Why?
| | Homeodomain Proteins | 2 | 2006 | 512 | 0.050 |
Why?
| | Sequence Analysis, RNA | 2 | 2017 | 447 | 0.050 |
Why?
| | Boron Compounds | 1 | 2024 | 30 | 0.050 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2024 | 9 | 0.050 |
Why?
| | Transglutaminases | 3 | 1995 | 156 | 0.050 |
Why?
| | Blotting, Southern | 3 | 2001 | 75 | 0.050 |
Why?
| | Aminopyridines | 1 | 2024 | 109 | 0.050 |
Why?
| | United States | 1 | 2021 | 15195 | 0.050 |
Why?
| | In Vitro Techniques | 4 | 2013 | 1093 | 0.050 |
Why?
| | Pregnancy | 5 | 2010 | 7035 | 0.050 |
Why?
| | Benzamides | 1 | 2024 | 220 | 0.050 |
Why?
| | Gene Editing | 1 | 2024 | 86 | 0.050 |
Why?
| | Receptors, Cell Surface | 2 | 2005 | 398 | 0.050 |
Why?
| | Tissue Distribution | 2 | 2002 | 327 | 0.050 |
Why?
| | Body Weight | 2 | 2011 | 992 | 0.050 |
Why?
| | Transplantation, Autologous | 1 | 2024 | 280 | 0.050 |
Why?
| | Time Factors | 5 | 2004 | 6944 | 0.050 |
Why?
| | Vimentin | 4 | 1994 | 52 | 0.050 |
Why?
| | Molecular Structure | 2 | 1994 | 501 | 0.050 |
Why?
| | Vitamin K 3 | 1 | 2002 | 3 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 153 | 0.050 |
Why?
| | Biomarkers | 5 | 2004 | 4175 | 0.050 |
Why?
| | Genetic Variation | 2 | 1998 | 994 | 0.050 |
Why?
| | S100 Proteins | 2 | 2000 | 36 | 0.050 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 252 | 0.050 |
Why?
| | Dacarbazine | 2 | 2012 | 95 | 0.050 |
Why?
| | Keratin-15 | 1 | 2002 | 17 | 0.050 |
Why?
| | Bioreactors | 1 | 2002 | 48 | 0.050 |
Why?
| | Keratin-5 | 1 | 2002 | 48 | 0.040 |
Why?
| | Immunoenzyme Techniques | 4 | 1993 | 207 | 0.040 |
Why?
| | Isomerism | 1 | 2001 | 55 | 0.040 |
Why?
| | Mesocricetus | 5 | 1993 | 45 | 0.040 |
Why?
| | 3T3 Cells | 3 | 2013 | 154 | 0.040 |
Why?
| | Vitamin A Deficiency | 3 | 1993 | 26 | 0.040 |
Why?
| | Starvation | 1 | 2001 | 23 | 0.040 |
Why?
| | Luteolytic Agents | 1 | 2001 | 1 | 0.040 |
Why?
| | Bone and Bones | 1 | 2004 | 313 | 0.040 |
Why?
| | Mouth Diseases | 1 | 2001 | 46 | 0.040 |
Why?
| | Lasers | 1 | 2002 | 130 | 0.040 |
Why?
| | Administration, Topical | 3 | 1997 | 149 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2004 | 430 | 0.040 |
Why?
| | Autoantibodies | 1 | 1988 | 1474 | 0.040 |
Why?
| | Benzo(a)pyrene | 1 | 2000 | 8 | 0.040 |
Why?
| | Response Elements | 2 | 2012 | 89 | 0.040 |
Why?
| | Nuclear Localization Signals | 1 | 2000 | 18 | 0.040 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2000 | 34 | 0.040 |
Why?
| | Frameshift Mutation | 1 | 2000 | 32 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2000 | 53 | 0.040 |
Why?
| | Dermatitis, Exfoliative | 1 | 2020 | 3 | 0.040 |
Why?
| | Netherton Syndrome | 1 | 2020 | 3 | 0.040 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 391 | 0.040 |
Why?
| | Cell Survival | 3 | 2013 | 1129 | 0.040 |
Why?
| | Adaptation, Biological | 1 | 2000 | 53 | 0.040 |
Why?
| | Rats | 5 | 1994 | 5594 | 0.040 |
Why?
| | Chickens | 9 | 1995 | 189 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 54 | 0.040 |
Why?
| | Immunoblotting | 4 | 2003 | 309 | 0.040 |
Why?
| | Zebrafish | 1 | 2004 | 504 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 59 | 0.040 |
Why?
| | Repressor Proteins | 2 | 2013 | 428 | 0.040 |
Why?
| | Cell Nucleus | 7 | 2004 | 607 | 0.040 |
Why?
| | Estrenes | 1 | 1999 | 16 | 0.040 |
Why?
| | DNA, Complementary | 2 | 2003 | 274 | 0.040 |
Why?
| | DNA, Neoplasm | 3 | 1995 | 157 | 0.040 |
Why?
| | Kidney | 1 | 2007 | 1475 | 0.040 |
Why?
| | Restriction Mapping | 1 | 1999 | 76 | 0.040 |
Why?
| | Genomic Library | 1 | 1999 | 17 | 0.040 |
Why?
| | Genetic Carrier Screening | 1 | 1999 | 30 | 0.040 |
Why?
| | Phototherapy | 1 | 2019 | 46 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2019 | 54 | 0.040 |
Why?
| | Forelimb | 1 | 1999 | 39 | 0.040 |
Why?
| | DNA Damage | 2 | 2012 | 429 | 0.040 |
Why?
| | RNA, Heterogeneous Nuclear | 1 | 1978 | 6 | 0.040 |
Why?
| | Sequence Analysis | 1 | 1998 | 36 | 0.040 |
Why?
| | Protein Transport | 1 | 2000 | 448 | 0.040 |
Why?
| | Reference Values | 3 | 2002 | 803 | 0.040 |
Why?
| | Dimerization | 1 | 1999 | 195 | 0.040 |
Why?
| | Thrombospondin 1 | 1 | 1998 | 28 | 0.040 |
Why?
| | Fungal Proteins | 1 | 1999 | 137 | 0.040 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 1998 | 79 | 0.040 |
Why?
| | Endothelial Growth Factors | 1 | 1998 | 64 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 2235 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2011 | 757 | 0.040 |
Why?
| | Peptides | 1 | 1984 | 979 | 0.040 |
Why?
| | Lymphokines | 1 | 1998 | 132 | 0.040 |
Why?
| | Body Patterning | 1 | 1999 | 136 | 0.040 |
Why?
| | Mutagenesis, Insertional | 1 | 1998 | 65 | 0.040 |
Why?
| | Genes, bcl-2 | 1 | 1998 | 22 | 0.040 |
Why?
| | Neovascularization, Physiologic | 1 | 1999 | 180 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2002 | 1022 | 0.030 |
Why?
| | Age of Onset | 1 | 1999 | 533 | 0.030 |
Why?
| | Psoriasis | 2 | 1996 | 110 | 0.030 |
Why?
| | Gamma Rays | 1 | 1998 | 57 | 0.030 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 1997 | 16 | 0.030 |
Why?
| | Antigens, Neoplasm | 2 | 1997 | 322 | 0.030 |
Why?
| | Thymus Gland | 1 | 1998 | 317 | 0.030 |
Why?
| | Oxazines | 1 | 1997 | 32 | 0.030 |
Why?
| | Epidermal Growth Factor | 3 | 1993 | 174 | 0.030 |
Why?
| | Retinoid X Receptors | 1 | 1997 | 38 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2006 | 2368 | 0.030 |
Why?
| | Protein Binding | 3 | 2009 | 2238 | 0.030 |
Why?
| | Mitotic Index | 1 | 1997 | 24 | 0.030 |
Why?
| | Metaplasia | 3 | 1993 | 58 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2000 | 837 | 0.030 |
Why?
| | Receptors, Calcitriol | 1 | 1997 | 55 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 1997 | 75 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 1997 | 53 | 0.030 |
Why?
| | Luciferases | 2 | 2009 | 148 | 0.030 |
Why?
| | Hybrid Cells | 2 | 1994 | 48 | 0.030 |
Why?
| | Carcinogenicity Tests | 2 | 1994 | 10 | 0.030 |
Why?
| | Interleukin-2 | 1 | 1998 | 451 | 0.030 |
Why?
| | Hypertrophy | 1 | 1997 | 134 | 0.030 |
Why?
| | Organ Culture Techniques | 4 | 1990 | 157 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 2 | 1987 | 114 | 0.030 |
Why?
| | Body Temperature | 1 | 1997 | 224 | 0.030 |
Why?
| | Hyaluronan Receptors | 1 | 2016 | 103 | 0.030 |
Why?
| | Extremities | 1 | 1997 | 139 | 0.030 |
Why?
| | Rats, Inbred F344 | 2 | 1993 | 267 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 1998 | 550 | 0.030 |
Why?
| | Rabbits | 2 | 1996 | 754 | 0.030 |
Why?
| | Kinetics | 5 | 1994 | 1651 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2016 | 77 | 0.030 |
Why?
| | Phospholipids | 1 | 1997 | 221 | 0.030 |
Why?
| | Biopsy | 2 | 1997 | 1069 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 1998 | 674 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2015 | 204 | 0.030 |
Why?
| | PAX3 Transcription Factor | 1 | 2015 | 17 | 0.030 |
Why?
| | Fluorescent Dyes | 1 | 1997 | 324 | 0.030 |
Why?
| | Paired Box Transcription Factors | 1 | 2015 | 43 | 0.030 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1995 | 154 | 0.030 |
Why?
| | Inhibins | 1 | 1995 | 42 | 0.030 |
Why?
| | Interleukins | 1 | 1997 | 250 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 67 | 0.030 |
Why?
| | Random Allocation | 1 | 2016 | 363 | 0.030 |
Why?
| | Cantharidin | 1 | 1994 | 1 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 344 | 0.030 |
Why?
| | Benzoates | 1 | 1995 | 49 | 0.030 |
Why?
| | Tetrahydronaphthalenes | 1 | 1995 | 30 | 0.030 |
Why?
| | Ainhum | 1 | 2014 | 1 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2015 | 68 | 0.030 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 1997 | 209 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 1998 | 1240 | 0.030 |
Why?
| | DNA Probes, HPV | 1 | 1994 | 1 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1994 | 172 | 0.030 |
Why?
| | Sequence Alignment | 1 | 1995 | 363 | 0.030 |
Why?
| | Actin Cytoskeleton | 1 | 1995 | 103 | 0.030 |
Why?
| | Staining and Labeling | 2 | 2010 | 152 | 0.030 |
Why?
| | Ornithine Decarboxylase | 1 | 1994 | 13 | 0.030 |
Why?
| | Epigen | 1 | 2014 | 1 | 0.030 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2014 | 6 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2020 | 852 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 713 | 0.030 |
Why?
| | Simian virus 40 | 1 | 1993 | 25 | 0.030 |
Why?
| | TATA Box | 1 | 1993 | 22 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2007 | 2552 | 0.030 |
Why?
| | Collagen Type IV | 1 | 2014 | 28 | 0.030 |
Why?
| | Chorionic Villi | 1 | 1994 | 25 | 0.030 |
Why?
| | Open Reading Frames | 1 | 1994 | 132 | 0.030 |
Why?
| | Laminin | 1 | 1994 | 72 | 0.030 |
Why?
| | alpha Catenin | 1 | 2013 | 11 | 0.030 |
Why?
| | Middle Aged | 5 | 2020 | 34487 | 0.030 |
Why?
| | Butylhydroxybutylnitrosamine | 1 | 1993 | 6 | 0.030 |
Why?
| | Multigene Family | 1 | 1994 | 202 | 0.030 |
Why?
| | Clone Cells | 2 | 2010 | 267 | 0.030 |
Why?
| | Cholecalciferol | 1 | 1994 | 61 | 0.030 |
Why?
| | Cell Dedifferentiation | 1 | 2013 | 31 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2014 | 240 | 0.030 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2013 | 50 | 0.030 |
Why?
| | Mice, Inbred CBA | 1 | 2013 | 54 | 0.030 |
Why?
| | Ovariectomy | 1 | 1994 | 158 | 0.030 |
Why?
| | Antigens, CD | 1 | 2016 | 544 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2020 | 11125 | 0.030 |
Why?
| | Sulfur Radioisotopes | 2 | 1990 | 15 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 428 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2009 | 6257 | 0.020 |
Why?
| | DNA Probes | 2 | 1992 | 59 | 0.020 |
Why?
| | Collagen Type I | 1 | 2014 | 140 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2016 | 608 | 0.020 |
Why?
| | Protein Biosynthesis | 6 | 1991 | 444 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2013 | 183 | 0.020 |
Why?
| | Glycoproteins | 1 | 1995 | 358 | 0.020 |
Why?
| | Chromosomes, Mammalian | 1 | 2012 | 28 | 0.020 |
Why?
| | Diseases in Twins | 1 | 1994 | 159 | 0.020 |
Why?
| | Lentivirus | 1 | 2013 | 59 | 0.020 |
Why?
| | Forecasting | 1 | 1994 | 383 | 0.020 |
Why?
| | Breast | 1 | 1993 | 155 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 27 | 0.020 |
Why?
| | Child | 3 | 2020 | 22313 | 0.020 |
Why?
| | Egg Proteins | 3 | 1982 | 21 | 0.020 |
Why?
| | Serine | 1 | 1993 | 148 | 0.020 |
Why?
| | Viruses | 1 | 1994 | 163 | 0.020 |
Why?
| | Bacteriophage lambda | 1 | 1993 | 89 | 0.020 |
Why?
| | Limb Buds | 2 | 2004 | 23 | 0.020 |
Why?
| | Coloring Agents | 1 | 2012 | 96 | 0.020 |
Why?
| | Cysteine | 1 | 1993 | 208 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 301 | 0.020 |
Why?
| | Tritium | 3 | 1994 | 72 | 0.020 |
Why?
| | Myoepithelioma | 1 | 1991 | 3 | 0.020 |
Why?
| | Mutagenicity Tests | 1 | 2011 | 15 | 0.020 |
Why?
| | Gene Knock-In Techniques | 1 | 2011 | 59 | 0.020 |
Why?
| | Avian Leukosis Virus | 1 | 2011 | 6 | 0.020 |
Why?
| | Age Factors | 2 | 1996 | 3278 | 0.020 |
Why?
| | Integrin-Binding Sialoprotein | 1 | 2011 | 5 | 0.020 |
Why?
| | Rodent Diseases | 1 | 1991 | 28 | 0.020 |
Why?
| | Ovomucin | 2 | 1982 | 10 | 0.020 |
Why?
| | Biological Evolution | 2 | 1985 | 486 | 0.020 |
Why?
| | Moloney murine leukemia virus | 1 | 1991 | 13 | 0.020 |
Why?
| | Haploinsufficiency | 1 | 2011 | 55 | 0.020 |
Why?
| | Hyperpigmentation | 1 | 2011 | 27 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 272 | 0.020 |
Why?
| | Osteocalcin | 1 | 2011 | 38 | 0.020 |
Why?
| | Proteome | 1 | 2015 | 483 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 235 | 0.020 |
Why?
| | Progesterone | 2 | 2010 | 258 | 0.020 |
Why?
| | Embryo Implantation | 1 | 2010 | 30 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1968 | 0.020 |
Why?
| | Wnt4 Protein | 1 | 2010 | 20 | 0.020 |
Why?
| | Growth Disorders | 1 | 2011 | 87 | 0.020 |
Why?
| | Immunosorbent Techniques | 2 | 1987 | 19 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 599 | 0.020 |
Why?
| | Infant | 2 | 2009 | 9790 | 0.020 |
Why?
| | Cytokines | 2 | 2015 | 2092 | 0.020 |
Why?
| | Swine | 1 | 1993 | 809 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 1997 | 915 | 0.020 |
Why?
| | Pigmentation | 1 | 2010 | 54 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 197 | 0.020 |
Why?
| | Urinary Bladder Neoplasms | 1 | 1993 | 255 | 0.020 |
Why?
| | Estrogens | 4 | 1982 | 367 | 0.020 |
Why?
| | Phospholipases A2 | 1 | 2010 | 83 | 0.020 |
Why?
| | Mouth Mucosa | 1 | 1990 | 90 | 0.020 |
Why?
| | Liver | 2 | 2002 | 1815 | 0.020 |
Why?
| | Animals, Wild | 1 | 1990 | 62 | 0.020 |
Why?
| | Adenoma, Pleomorphic | 1 | 1990 | 10 | 0.020 |
Why?
| | Parotid Neoplasms | 1 | 1990 | 15 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1994 | 1491 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1815 | 0.020 |
Why?
| | DNA Repair | 1 | 2012 | 239 | 0.020 |
Why?
| | Transcriptome | 1 | 2016 | 1007 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2009 | 44 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 1998 | 2003 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2009 | 90 | 0.020 |
Why?
| | Child, Preschool | 2 | 2009 | 11462 | 0.020 |
Why?
| | Arachidonic Acid | 1 | 2010 | 126 | 0.020 |
Why?
| | Amino Acids | 4 | 2002 | 493 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 1990 | 269 | 0.020 |
Why?
| | Anemia | 1 | 2011 | 176 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1999 | 5194 | 0.020 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2009 | 136 | 0.020 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2009 | 89 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 254 | 0.020 |
Why?
| | Dinoprostone | 1 | 2010 | 189 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2010 | 175 | 0.020 |
Why?
| | Diethylstilbestrol | 2 | 1979 | 9 | 0.020 |
Why?
| | Dystonin | 1 | 1988 | 1 | 0.020 |
Why?
| | Ameloblastoma | 1 | 1988 | 5 | 0.020 |
Why?
| | Cell Communication | 1 | 2010 | 316 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 3578 | 0.020 |
Why?
| | Methionine | 1 | 1989 | 159 | 0.020 |
Why?
| | Lactation | 1 | 1990 | 192 | 0.020 |
Why?
| | Tissue Scaffolds | 1 | 2011 | 213 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2010 | 206 | 0.020 |
Why?
| | Vitamin A | 2 | 1986 | 56 | 0.020 |
Why?
| | gamma-Glutamyltransferase | 1 | 1988 | 42 | 0.020 |
Why?
| | Piperazines | 1 | 2010 | 371 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 508 | 0.020 |
Why?
| | Isoelectric Point | 1 | 1987 | 23 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 1988 | 83 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 851 | 0.020 |
Why?
| | Survival Analysis | 1 | 2010 | 1320 | 0.020 |
Why?
| | Protease Inhibitors | 1 | 1988 | 104 | 0.020 |
Why?
| | Interferon-gamma | 1 | 1990 | 789 | 0.020 |
Why?
| | Antigens, Ly | 1 | 1987 | 43 | 0.020 |
Why?
| | Organoids | 1 | 1988 | 129 | 0.020 |
Why?
| | Harvey murine sarcoma virus | 1 | 1986 | 1 | 0.020 |
Why?
| | Dimethyl Sulfoxide | 1 | 1987 | 41 | 0.020 |
Why?
| | Occludin | 1 | 2006 | 12 | 0.020 |
Why?
| | LIM Domain Proteins | 1 | 2006 | 20 | 0.020 |
Why?
| | Claudin-1 | 1 | 2006 | 15 | 0.020 |
Why?
| | Olfactory Bulb | 1 | 2008 | 98 | 0.020 |
Why?
| | Minichromosome Maintenance Complex Component 7 | 1 | 2006 | 4 | 0.020 |
Why?
| | Interleukin-6 | 1 | 1990 | 777 | 0.020 |
Why?
| | Immunoassay | 1 | 1987 | 113 | 0.020 |
Why?
| | Receptors, Steroid | 1 | 2006 | 46 | 0.020 |
Why?
| | Chemistry | 1 | 1985 | 44 | 0.010 |
Why?
| | Chemical Phenomena | 1 | 1985 | 82 | 0.010 |
Why?
| | Fluocinolone Acetonide | 1 | 1985 | 15 | 0.010 |
Why?
| | X-Ray Diffraction | 1 | 1985 | 104 | 0.010 |
Why?
| | Calcium-Binding Proteins | 1 | 1986 | 217 | 0.010 |
Why?
| | Microscopy, Electron, Scanning | 1 | 1985 | 203 | 0.010 |
Why?
| | HeLa Cells | 1 | 2007 | 639 | 0.010 |
Why?
| | Phosphorylation | 1 | 2009 | 1758 | 0.010 |
Why?
| | Erythroid-Specific DNA-Binding Factors | 1 | 2004 | 15 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2128 | 0.010 |
Why?
| | Cattle | 2 | 1988 | 991 | 0.010 |
Why?
| | Calcineurin Inhibitors | 1 | 2005 | 70 | 0.010 |
Why?
| | YY1 Transcription Factor | 1 | 2004 | 22 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 1 | 1987 | 463 | 0.010 |
Why?
| | NFATC Transcription Factors | 1 | 2005 | 94 | 0.010 |
Why?
| | Base Composition | 1 | 1984 | 79 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2004 | 34 | 0.010 |
Why?
| | Thymidine | 2 | 1994 | 60 | 0.010 |
Why?
| | Antigen-Antibody Complex | 1 | 1984 | 87 | 0.010 |
Why?
| | Aged | 3 | 2020 | 24666 | 0.010 |
Why?
| | Fibroblast Growth Factor 8 | 1 | 2004 | 27 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1988 | 972 | 0.010 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2004 | 68 | 0.010 |
Why?
| | src-Family Kinases | 1 | 2004 | 94 | 0.010 |
Why?
| | Stomach Diseases | 1 | 2003 | 19 | 0.010 |
Why?
| | Weaning | 1 | 2003 | 46 | 0.010 |
Why?
| | Craniofacial Abnormalities | 1 | 2004 | 75 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 13646 | 0.010 |
Why?
| | Esophageal Diseases | 1 | 2003 | 28 | 0.010 |
Why?
| | Antibodies, Monoclonal | 2 | 1990 | 1471 | 0.010 |
Why?
| | Terminology as Topic | 1 | 1985 | 244 | 0.010 |
Why?
| | Mice, Hairless | 2 | 1994 | 59 | 0.010 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2003 | 67 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1031 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 1987 | 556 | 0.010 |
Why?
| | Adolescent | 2 | 2020 | 22027 | 0.010 |
Why?
| | Fibroblast Growth Factors | 1 | 2004 | 185 | 0.010 |
Why?
| | Aging | 1 | 1993 | 1917 | 0.010 |
Why?
| | Cheek | 2 | 1993 | 17 | 0.010 |
Why?
| | Fertility | 1 | 2002 | 165 | 0.010 |
Why?
| | RNA, Small Nuclear | 1 | 1981 | 37 | 0.010 |
Why?
| | Mice, Inbred A | 1 | 2000 | 51 | 0.010 |
Why?
| | Biotransformation | 1 | 2000 | 62 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1984 | 698 | 0.010 |
Why?
| | Risk Factors | 1 | 1994 | 10430 | 0.010 |
Why?
| | Sequence Homology | 1 | 1999 | 43 | 0.010 |
Why?
| | Limb Deformities, Congenital | 1 | 1999 | 21 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 2056 | 0.010 |
Why?
| | Neurons | 1 | 2008 | 1615 | 0.010 |
Why?
| | Phosphorus Radioisotopes | 1 | 1978 | 27 | 0.010 |
Why?
| | Globins | 1 | 1978 | 21 | 0.010 |
Why?
| | Reticulocytes | 1 | 1978 | 17 | 0.010 |
Why?
| | Cholera Toxin | 2 | 1988 | 31 | 0.010 |
Why?
| | Polyribosomes | 1 | 1978 | 24 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1998 | 101 | 0.010 |
Why?
| | Antibody Specificity | 2 | 1989 | 187 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 1998 | 41 | 0.010 |
Why?
| | Drug Stability | 1 | 1978 | 165 | 0.010 |
Why?
| | Isotope Labeling | 1 | 1978 | 81 | 0.010 |
Why?
| | RNA Polymerase II | 1 | 1981 | 339 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 1998 | 335 | 0.010 |
Why?
| | Immunologic Techniques | 2 | 1986 | 39 | 0.010 |
Why?
| | Desmogleins | 1 | 1996 | 3 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1998 | 414 | 0.010 |
Why?
| | Desmoplakins | 1 | 1996 | 27 | 0.010 |
Why?
| | Receptors, Estrogen | 1 | 1979 | 411 | 0.010 |
Why?
| | Follistatin | 1 | 1995 | 12 | 0.010 |
Why?
| | Vibrissae | 1 | 1995 | 10 | 0.010 |
Why?
| | Activins | 1 | 1995 | 29 | 0.010 |
Why?
| | Musculoskeletal Abnormalities | 1 | 1995 | 14 | 0.010 |
Why?
| | Xenopus | 1 | 1995 | 89 | 0.010 |
Why?
| | Palate | 1 | 1995 | 40 | 0.010 |
Why?
| | Musculoskeletal System | 1 | 1995 | 49 | 0.010 |
Why?
| | Estrus | 1 | 1994 | 11 | 0.010 |
Why?
| | Acetone | 1 | 1994 | 12 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1998 | 719 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 1997 | 501 | 0.010 |
Why?
| | Lymph Nodes | 1 | 1997 | 500 | 0.010 |
Why?
| | Skull | 1 | 1995 | 147 | 0.010 |
Why?
| | Dendritic Cells | 1 | 1997 | 502 | 0.010 |
Why?
| | Cell Fusion | 1 | 1993 | 50 | 0.010 |
Why?
| | Protein Kinase C | 1 | 1994 | 252 | 0.010 |
Why?
| | Organelles | 1 | 1991 | 56 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 1991 | 145 | 0.010 |
Why?
| | Retroviridae | 1 | 1991 | 103 | 0.010 |
Why?
| | Peptide Mapping | 1 | 1990 | 65 | 0.010 |
Why?
| | Trypsin | 1 | 1990 | 76 | 0.010 |
Why?
| | von Willebrand Factor | 1 | 1990 | 84 | 0.000 |
Why?
| | DNA, Recombinant | 2 | 1979 | 48 | 0.000 |
Why?
| | RNA Probes | 1 | 1988 | 13 | 0.000 |
Why?
| | Autoradiography | 1 | 1988 | 69 | 0.000 |
Why?
| | HLA-DR Antigens | 1 | 1990 | 227 | 0.000 |
Why?
| | Histocytochemistry | 1 | 1988 | 80 | 0.000 |
Why?
| | Metaphase | 1 | 1988 | 32 | 0.000 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 1988 | 50 | 0.000 |
Why?
| | Cytoplasm | 1 | 1988 | 272 | 0.000 |
Why?
| | Microbial Collagenase | 1 | 1987 | 13 | 0.000 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 1988 | 111 | 0.000 |
Why?
| | Culture Techniques | 1 | 1987 | 74 | 0.000 |
Why?
| | Cross Reactions | 1 | 1988 | 133 | 0.000 |
Why?
| | Light | 1 | 1990 | 395 | 0.000 |
Why?
| | Leukemia, Radiation-Induced | 1 | 1987 | 4 | 0.000 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1987 | 39 | 0.000 |
Why?
| | Leukemia, Experimental | 1 | 1987 | 28 | 0.000 |
Why?
| | Cricetulus | 1 | 1987 | 111 | 0.000 |
Why?
| | Diterpenes | 1 | 1986 | 27 | 0.000 |
Why?
| | Genetic Markers | 1 | 1987 | 342 | 0.000 |
Why?
| | Inflammation | 1 | 1997 | 2891 | 0.000 |
Why?
| | Incidence | 1 | 1991 | 2782 | 0.000 |
Why?
| | Lipopolysaccharides | 1 | 1988 | 887 | 0.000 |
Why?
| | Aged, 80 and over | 1 | 1996 | 7899 | 0.000 |
Why?
| | Poly A | 1 | 1982 | 51 | 0.000 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 1979 | 63 | 0.000 |
Why?
| | Retrospective Studies | 1 | 1991 | 16315 | 0.000 |
Why?
|
|
Roop's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|